AN2 Therapeutics director Robin Shane Readnour disposes of USD 212,486 common shares
ANTX•Director reports common share sales
- AN2 Therapeutics director Robin Shane Readnour reported sales of 35,402 common shares on Aug. 17.
- Shares sold at a weighted average price of $6.01.
- Indirect holdings stood at 565,592 shares via MGC Venture Partners 2018, LP.
- Indirect holdings stood at 633,867 shares via MGC Venture Partners QP 2018, LP.
- Readnour also held 9,077 shares directly following the transactions.
